Biomedical Occupation or Discipline – Page 12

Servier and Google Cloud Extend Partnership to Accelerate AI-Powered Drug Development

6 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, digital transformation, Drug Development, generative, Google Cloud, Pharmaceutical Research, R&D, Servier, therapeutic solutions

Servier, Google Cloud, AI, drug development, pharmaceutical research, digital transformation, R&D, generative AI, gen AI, therapeutic solutions.

Pharmaceutical CEOs Emphasize Transparency to Counter Anti-Vaccine Sentiment in the US

6 months ago talkbio0Tagged anti-vaccine, public health medicine (field), sanofi, SmithKline Beecham, Translucent, Urinary hesitation, Vaccines

Anti-vaccine movement, Transparency, GSK, Sanofi, Vaccine hesitancy, Public health

Bioptimus Secures $76M Funding to Develop Revolutionary AI Foundation Model for Biology

6 months ago talkbio0Tagged Alanine Transaminase, Aortic Valve Insufficiency, Artificial Intelligence, biology (field), Bioptimus, Cathay Innovation, Drug Industry, medical innovation, Study models

Bioptimus, AI foundation model, biology, funding, Cathay Innovation, GPT of biology, biological research, pharmaceutical industry, biotech, medical innovation.

Denali and AbbVie’s ALS Candidates Fail Phase 2/3 Trials, Highlighting Challenges in ALS Research

6 months ago talkbio0Tagged AbbVie, Amyotrophic Lateral Sclerosis, Calico Life Sciences, Clinical Trials, Denali, DNL343, Drug Development, fosigotifator, HEALEY

ALS, Denali Therapeutics, AbbVie, Calico Life Sciences, HEALEY ALS Platform Trial, DNL343, fosigotifator, amyotrophic lateral sclerosis, clinical trials, drug development

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion to Strengthen Neuroscience Portfolio

6 months ago talkbio0Tagged Acquisition, Biological Factors, Caplyta, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Biopharmaceutical

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio

6 months ago talkbio0Tagged Acquisition, Caplyta, Depression, Bipolar, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline, Schizophrenia

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Bipolar Depression, Schizophrenia, Major Depressive Disorder

Biogen Proposes Acquisition of Sage Therapeutics in $442 Million Deal

6 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Depressive disorder, Neurology speciality, zuranolone

Biogen, Sage Therapeutics, acquisition, neuro biotech, zuranolone, postpartum depression, major depressive disorder

Gilead and LEO Pharma Collaborate on STAT6 Inflammatory Disease Programmes

6 months ago talkbio0Tagged Dermatology field, Gilead Sciences, Inflammatory disorder, oral formulations, Partnership, Pharma, STAT6

Gilead Sciences, LEO Pharma, STAT6, inflammatory diseases, partnership, oral formulations, dermatology

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio

6 months ago talkbio0Tagged Acquisition, Biopharma, Caplyta, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, M&A, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Lumateperone, CAPLYTA, Biopharma, M&A

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio

6 months ago talkbio0Tagged Acquisition, Caplyta, Depression, Bipolar, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline, Schizophrenia

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Caplyta, Lumateperone, Schizophrenia, Bipolar Depression, Major Depressive Disorder